Group 1 - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. to recover losses for shareholders affected by alleged securities fraud between February 21, 2025, and August 28, 2025 [2][3] - The complaint alleges that the defendants made false statements regarding Telix's progress with prostate cancer therapeutic candidates, overstated the quality of its supply chain and partners, and that these statements were materially false and misleading [3] - Shareholders who suffered losses during the relevant time frame are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4] Group 2 - Levi & Korsinsky LLP is a nationally recognized securities litigation firm with a track record of securing hundreds of millions of dollars for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [5]

New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177904&wire=5&utm_campaign=29or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Can ...

Core Viewpoint - A class action securities lawsuit has been filed against Molina Healthcare, Inc. to recover losses incurred by shareholders due to alleged securities fraud between February 5, 2025, and July 23, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed material adverse facts regarding the company's medical cost trend assumptions [3]. - It is alleged that Molina was experiencing a dislocation between premium rates and medical cost trends, which was not disclosed [3]. - The complaint indicates that Molina's near-term growth relied on a lack of utilization of behavioral health, pharmacy, and inpatient and outpatient services [3]. - As a result of these issues, Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced, and the positive statements made by the defendants about the company's business were misleading [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5]. - The firm has over 20 years of experience and has been consistently ranked among the top securities litigation firms in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. due to alleged securities fraud that affected shareholders between November 7, 2024, and September 12, 2025 [2][3]. Company Details - The lawsuit claims that aTyr Pharma provided misleading positive statements about the efficacy of its drug Efzofitimod while concealing material adverse facts regarding its ability to allow patients to taper off steroid usage [3][4]. - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [4]. Stock Performance - Following the announcement of the study results, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a significant decline of 83.2% in just one day [5]. Legal Action - Shareholders who suffered losses during the relevant timeframe are encouraged to seek recovery, with no cost or obligation to participate in the lawsuit [6]. Firm Background - Levi & Korsinsky LLP, the firm handling the lawsuit, has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [7].

SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake as well as certain of MoonLake’s executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Moon ...

Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving StubHub Holdings, Inc. [1][7] Company Overview - StubHub operates a ticketing marketplace for live event tickets worldwide [2]. Investigation Details - The investigation focuses on whether StubHub and certain top executives made materially false and/or misleading statements and/or omitted material information regarding StubHub's business and operations [3]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm representing investors in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [4]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors [4]. - Robbins Geller is one of the largest plaintiffs' firms globally, with 200 lawyers in 10 offices [4].

Core Points - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock about the lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from December 27, 2023, to May 6, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Cytokinetics common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 17, 2025 [3]. - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a record settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Molina Healthcare failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and the impact on financial guidance for fiscal year 2025 [5]. - Specific claims include a dislocation between premium rates and medical costs, reliance on limited service utilization for growth, and misleading positive statements about the company's business prospects [5].

Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Marex securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by December 8, 2025 [3]. - The lawsuit alleges that Marex made materially false and misleading statements and failed to disclose critical information regarding its financial practices, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in the number of settlements since 2013 [4].

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Freeport, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/freeport-mcmoran-inc-clas ...